The Kron laboratory is a diverse and collaborative group of cell biologists, geneticists, biochemists, chemists and computer scientists. Our current basic research and technology efforts include 1) defining roles for chromatin dynamics and cell cycle regulation in DNA damage checkpoint response and cellular senescence, 2) dissecting cross-talk between metabolism and DNA damage response, 3) developing novel molecular assays to interrogate cell signaling in cancer, and 4) implementing novel mass spectrometry approaches to enable quantitative proteomics. We also pursue translational projects directed at 1) discovering inhibitors of cellular response to DNA double strand breaks as an approach to radiosensitization, 2) examining DNA damage and repair in tissues and tumors, and 3) exploiting DNA damage responses to induce anti-tumor immune responses.
Whitehead Institute
Cambridge MA
- Genetics
1995
Stanford University
Stanford CA
PhD - Cell Biology
1990
Stanford University
Stanford CA
MD - Medicine
1990
University of Pennsylvania
Philadelphia PA
MSE - Bioengineering
1983
University of Pennsylvania
Philadelphia PA
BA - Biochemistry
1982
Telomerase reverse transcriptase degradation via a rationally designed covalent proteolysis targeting chimera.
Telomerase reverse transcriptase degradation via a rationally designed covalent proteolysis targeting chimera. Bioorg Med Chem Lett. 2025 Sep 01; 125-126:130286.
PMID: 40412449
Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation.
Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation. Cancers (Basel). 2025 Jan 24; 17(3).
PMID: 39941761
Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites.
Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites. Redox Biol. 2025 Mar; 80:103504.
PMID: 39879737
Could senescent cells be the prescription for therapeutic cancer vaccines?
Could senescent cells be the prescription for therapeutic cancer vaccines? Immunotherapy. 2024; 16(18-19):1091-1093.
PMID: 39545612
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence? Cells. 2024 07 30; 13(15).
PMID: 39120312
Context-dependent roles for autophagy in myeloid cells in tumor progression.
Context-dependent roles for autophagy in myeloid cells in tumor progression. bioRxiv. 2024 Jul 16.
PMID: 39071306
CUX1 regulates human hematopoietic stem cell chromatin accessibility via the BAF complex.
CUX1 regulates human hematopoietic stem cell chromatin accessibility via the BAF complex. Cell Rep. 2024 05 28; 43(5):114227.
PMID: 38735044
Protocol for examining the capability of senescent tumor cells to stimulate murine bone-marrow-derived dendritic cells by flow cytometry.
Protocol for examining the capability of senescent tumor cells to stimulate murine bone-marrow-derived dendritic cells by flow cytometry. STAR Protoc. 2023 12 15; 4(4):102677.
PMID: 37897729
Statins in Cancer Prevention and Therapy.
Statins in Cancer Prevention and Therapy. Cancers (Basel). 2023 Aug 03; 15(15).
PMID: 37568764
Sel1-like proteins and peptides are the major Oxalobacter formigenes-derived factors stimulating oxalate transport by human intestinal epithelial cells.
Sel1-like proteins and peptides are the major Oxalobacter formigenes-derived factors stimulating oxalate transport by human intestinal epithelial cells. Am J Physiol Cell Physiol. 2023 07 01; 325(1):C344-C361.
PMID: 37125773